SVRA | Ticker Profile - Titan Protect

SVRA

Savara Inc.

Healthcare · Biotechnology · NMS

$5.09

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.1B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-14.37

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-80.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$10.25

+101% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 8 analysts covering this stock

About Savara Inc.

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

https://www.savarapharma.com

Country: United States Employees: 70 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.490

Positive but modest risk-adjusted returns

Kelly Fraction

0.0072

Marginal edge — very small allocation suggested

Calmar Ratio

0.175

Drawdown risk outweighs the returns — higher risk profile

Annual Return

10.8%

Historical annualised return based on price data

Max Drawdown

-61.7%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

110

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.28

Very low correlation to market moves

52W High

$7.01

27% below the year high

52W Low

$1.93

164% above the year low

Avg Volume

1,455,360

Average daily shares traded — higher means easier to buy and sell

Short Ratio

22.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.9%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.56

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.11

Heavy leverage — higher financial risk if revenues decline

Current Ratio

13.47

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

13.21

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-57,653,624

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-129,482,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$16.00

Target Median

$10.25

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go